VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
TLXTelix Pharmaceuticals Limited
$10.00$3.4B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksTLXEarnings History

TLX logoTelix Pharmaceuticals Limited (TLX) Earnings History

Profitable

9 years of earnings data (2017–2025) · Positive TTM net income

TTM Net Income
$39M
● Profitable
TTM EPS (Diluted)
$0.12
Per share, diluted
YoY EPS Growth
-122.6%
Declining
Net Margin
-0.9%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin2.2%
Gross Margin53.1%
Return on Equity-1.8%
Return on Assets-0.7%
Record Annual Net Income$50MFY2024
Record Quarterly EPS$0.11Q4 2024
Consecutive Profitable Years0years
Q4 2025
Net Income-$7M
EPS (Diluted)$-0.02
YoY Growth-122.6%Declining
QoQ Growth-108.3%Declining

Loading earnings history...

Telix Pharmaceuticals Limited (TLX) Earnings Overview

As of June 23, 2026, Telix Pharmaceuticals Limited (TLX) reported trailing twelve-month net income of $39M, reflecting -122.6% year-over-year growth. The company earned $0.12 per diluted share over the past four quarters, with a net profit margin of -0.9%.

Looking at the long-term picture, TLX's historical earnings data spans multiple years. The company achieved its highest annual net income of $50M in fiscal 2024.

Telix Pharmaceuticals Limited maintains positive profitability with a gross margin of 53.1%, operating margin of 2.2%, and net margin of -0.9%. The company continues to generate positive earnings from operations. View revenue history →

Compared to peers including EXEL ($833M net income, 33.7% margin), RNW ($10.40B net income, 7.9% margin), AGEN ($65M net income, 0.1% margin), TLX has room to improve margins relative to the peer group. Compare TLX vs EXEL →

TLX Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
TLX logoTLXCurrent
$39M$0.12-0.9%-1.8%-122.6%—
EXEL logoEXEL
$833M$3.1233.7%35.5%+58.0%
RNW logoRNW
$10.4B$28.057.9%8.0%+172.4%
AGEN logoAGEN
$65M$1.690.1%-+100.0%
LNTH logoLNTH
$279M$4.2415.2%21.4%-21.8%
NVS logoNVS
$13.5B$7.0625.6%31.0%+22.5%
Best in group
Lowest in group

TLX Historical Earnings Data (2017–2025)

9 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$11M-121.4%$27M$-0.03-0.9%2.2%
2024$50M+858.0%$82M$0.146.4%10.5%
2023$5M+105.0%$16M$0.021.0%3.2%
2022-$104M-29.3%-$92M$-0.34-65.0%-57.4%
2021-$81M-79.4%-$81M$-0.29-1059.9%-1069.6%
2020-$45M-61.1%-$44M$-0.17-861.1%-847.7%
2019-$28M-101.5%-$36M$-0.12-799.6%-1033.6%
2018-$14M-116.9%-$29M$-0.07-7087.1%-15016.1%
2017-$6M--$7M$-0.05--

Download Data

Export TLX earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

9+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TLX — Frequently Asked Questions

Quick answers to the most common questions about buying TLX stock.

What is TLX earnings per share (EPS)?

TLX trailing twelve-month (TTM) diluted EPS is $0.12, reflecting -122.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.

What is Telix Pharmaceuticals Limited's net income?

Telix Pharmaceuticals Limited (TLX) trailing twelve-month net income is $39M as of 2025. Earnings declined -122.6% year-over-year.

Is TLX profitable?

Yes, TLX is profitable with a TTM net income of $39M and a net profit margin of -0.9%.

What is TLX's earnings growth rate?

TLX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.

What are TLX's profit margins?

Telix Pharmaceuticals Limited net profit margin is -0.9%, operating margin is +2.2%, and gross margin is +53.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is -1.8%.

Is TLX growing earnings?

TLX earnings are declining — EPS fell -122.6% year-over-year. TTM net income dropped to $39M. This contrasts with the 5-year CAGR of N/A.

What was TLX's best earnings year?

Telix Pharmaceuticals Limited's highest annual net income on record is $50M, achieved in fiscal year 2024. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.

What were TLX's earnings last quarter?

TLX's most recent reported quarter was Q4 2025. Net income was $-7M with diluted EPS of $-0.02. For a full breakdown of all quarters, see the quarterly earnings table on this page.

TLX Earnings Over Time (2017–2025)

Net income & EPS — annual and quarterly view